Analysts Offer Insights on Healthcare Companies: Phasebio Pharmaceuticals (NASDAQ: PHAS) and TFF Pharmaceuticals (NASDAQ: TFFP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Phasebio Pharmaceuticals (PHASResearch Report) and TFF Pharmaceuticals (TFFPResearch Report) with bullish sentiments.

Phasebio Pharmaceuticals (PHAS)

In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Phasebio Pharmaceuticals, with a price target of $8.00. The company’s shares closed last Thursday at $3.94.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.0% and a 46.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Phasebio Pharmaceuticals is a Strong Buy with an average price target of $14.00.

See today’s analyst top recommended stocks >>

TFF Pharmaceuticals (TFFP)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on TFF Pharmaceuticals, with a price target of $31.00. The company’s shares closed last Thursday at $11.26.

According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 27.8% and a 57.0% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Frequency Therapeutics.

TFF Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $29.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.